Table 4 Clinical efficacy and death evaluation during follow-up
TF group | TS group | p | |
|---|---|---|---|
Loss of follow up | 5/84 (6.0%) | 4/65 (6.2%) | 1.0000 |
Clinical efficacy evaluation, N (%) | |||
Cured | 33 (39.3%) | 29 (44.6%) | 0.6154 |
Improved | 20 (23.8%) | 20 (30.8%) | 0.3576 |
Invalid | 2 (2.4%) | 3 (4.6%) | 0.6534 |
Death | 24 (28.6%) | 9 (13.8%) | 0.0458 |
Causes of death, N (%) | |||
Tumor progression | 21 (25.0%) | 5 (7.7%) | 0.0081 |
Asphyxia | 1 (1.2%) | 4 (6.2%) | 0.1679 |
Massive bleeding | 2 (2.4%) | 0 (0.0%) | 0.5048 |